Pivotal Phase 3 Study Shows Ralinepag Achieved 55% Reduction in Clinical Worsening for PAH Patients
UTHR sits 85% above its 52-week low of $266.98.
Summary
United Therapeutics announced highly positive Phase 3 ADVANCE OUTCOMES study results for ralinepag, demonstrating a significant 55% reduction in the risk of clinical worsening in pulmonary arterial hypertension (PAH) patients.
Key Events · Product Development and Regulatory · UTHR
-
Pivotal Phase 3 Study Met Primary Endpoint
The ADVANCE OUTCOMES clinical study of ralinepag achieved its primary endpoint, reducing the risk of a clinical worsening event by 55% compared to placebo in patients with pulmonary arterial hypertension (PAH) (p<0.0001).
-
Significant Improvements in Secondary Endpoints
Ralinepag demonstrated statistically significant improvements in important secondary endpoints, including six-minute walk distance (6MWD) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), increasing the odds of clinical improvement by 47%.
-
Favorable Safety Profile
Treatment with ralinepag was well-tolerated, with a safety profile consistent with known prostacyclin-related adverse events and no new safety signals observed.
-
NDA Submission Planned for H2 2026
United Therapeutics intends to submit a New Drug Application (NDA) for ralinepag to the U.S. Food and Drug Administration (FDA) by the second half of 2026.
Analysis · UTHR · Life Sciences
United Therapeutics announced highly positive Phase 3 clinical trial results for ralinepag, a drug candidate for pulmonary arterial hypertension (PAH). The significant 55% reduction in clinical worsening events, coupled with improvements in key secondary endpoints, de-risks this major pipeline asset and positions ralinepag as a potential game-changer in PAH treatment. The company's plan to submit a New Drug Application (NDA) to the FDA by the second half of 2026 indicates a clear and accelerated path towards commercialization, which could substantially impact future revenue and market share in the PAH therapeutic area.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UTHR was trading at $495.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.1B. The 52-week trading range was $266.98 to $537.19. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.